NEI Steering Committee

Dr. Cutler has been conducting clinical research since 1993 and has been a Principal Investigator on over 400 clinical trials in a variety of CNS and medical indications, focusing on ADHD, Bipolar Disorder, Depression and Schizophrenia in children, adolescents, and adults. He was an Assistant Professor of Psychiatry at the University of Chicago before moving to Florida and founding Florida Clinical Research Center (FCRC) in 1998. He sold FCRC to Meridien Research in 2016. He retired from Meridien as Executive VP and Chief Medical Officer in 2019. He has authored more than 100 peer-reviewed scientific articles and has presented more than 300 abstracts and posters at scientific meetings around the world. He is a peer reviewer for several prominent medical journals and has served on several editorial boards. He has chaired or attended over 250 medical and scientific advisory boards, delivered more than 3,000 national and international pharmaceutical promotional talks, and over 300 continuing medical education (CME) and Grand rounds presentations. He has participated in more than 50 national satellite TV medical education broadcasts and led 200-plus national medical web conferences. Dr. Cutler consults extensively with pharmaceutical and biotechnology companies and serves on the board of the Neuroscience Education Institute.

Dr. Cutler is a member of the American Psychiatric Association (APA), the Florida Psychiatric Society (FPS) and the American Medical Association (AMA). He is honored to be a Fellow of both the APA and the Academy of Psychosomatic Medicine. He has received many professional honors and awards, including the Merck Award for outstanding medical scholarship, the University of Virginia Pride Award for outstanding patient care, the William Sorum Award from the APA, the Outstanding Congressional Fellow Award from the 103rd US Congress, a citation from Florida Hospital for outstanding patient care, and the Distinguished Clinical Professional Award from the Central Florida Mental Health Association.

Curriculum Vitae

Dr. McIntyre was named by Clarivate Analytics in 2014, 2015, 2016, 2017, 2018, 2019, 2020, 2021 and 2022 as one of “The World’s Most Influential Scientific Minds”. This distinction is given by publishing the largest number of articles that rank among those most frequently cited by researchers globally in 21 broad fields of science and social science during the previous decade. Dr. McIntyre has authored/co-authored more than 850 articles/manuscripts and has edited and/or co-edited several textbooks on mood disorders.

Dr. McIntyre is involved in multiple research endeavors which primarily aim to characterize the phenomenology, neurobiology, and novel therapeutics of mood disorders. Dr. McIntyre has been especially interested in identifying innovative, rapid acting psychotropic treatments for mood disorders. Dr. McIntyre’s research has also extended into public health and implementation research at the population-based level.

Dr. McIntyre is extensively involved in medical education. He is a highly sought-after speaker at both national and international meetings. He has received several teaching awards from the University of Toronto, Department of Psychiatry and has been a recipient of the joint Canadian Psychiatric Association (CPA) / Council of Psychiatric Continuing Education Award for the Most Outstanding Continuing Education Activity in Psychiatry in Canada.

Dr. McIntyre has also contributed extensively to clinical practice guidelines. For example, Dr. McIntyre is the lead author the "Florida Best Practice Psychotherapeutic Medication Guidelines for Adults with Major Depressive Disorder and Bipolar Disorder". In addition, Dr. McIntyre is also the lead author of the "International Expert Opinion on the Available Evidence and Implementation of Ketamine and Esketamine in Mood Disorders". Dr. McIntyre is also a contributor to the “Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the treatment of Depressive Disorders and Bipolar Disorders" as well as the "Royal Australian and New Zealand College of Psychiatrists Clinical Practice Guidelines for Mood Disorders".

Dr. McIntyre completed his medical degree at Dalhousie University. He received his Psychiatry residency training and Fellowship in Psychiatric Pharmacology at the University of Toronto.

Curriculum Vitae

His research focuses on anxiety disorders and risk factors for these conditions as well as on the pharmacologic treatment of these disorders. His research has been funded by the National Institute of Mental Health, the National Institute of Environmental Health Sciences, the Eunice Kennedy Shriver National Institute of Child Health and Human Development, and the Patient-Centered Outcomes Research Institute.

With his collaborators, Dr. Strawn uses neuroimaging, pharmacogenetics, and pharmacologic approaches to identify early predictors of treatment response and medication tolerability in anxiety disorders. His work aims to identify the best treatments for individual patients based on patient-specific characteristics and to characterize the trajectory of improvement. This work has provided a platform for refining treatment targets and identifying treatment response biomarkers in anxiety and related disorders.

Dr. Strawn has authored more than 220 peer-reviewed publications and authored 6 books on the treatment of children and adolescents, on pediatric psychopharmacology and on contemporary psychotherapy in addition to co-authoring the Prescriber’s Guide: Children & Adolescents with Dr. Stahl. He is a distinguished fellow of the American Academy of Child & Adolescent Psychiatry, a member of the American College of Neuropsychopharmacology and has received multiple awards for teaching, mentorship, and research.

Curriculum Vitae

Dr. Stephen M. Stahl received his undergraduate and medical degrees from Northwestern University in Chicago, as a member of the Honors Program in Medical Education, and his Ph.D. degree in pharmacology and physiology from the University of Chicago. Dr. Stahl has trained in three specialties: internal medicine at the University of Chicago; neurology at the University of California in San Francisco; and psychiatry at Stanford University. He is board certified in psychiatry.

Dr. Stahl has held faculty positions at Stanford University, the University of California at Los Angeles (UCLA), the Institute of Psychiatry London, the Institute of Neurology London, and, currently at the University of California Riverside, the University of California San Diego, the State University of New York Upstate Medical University at Syracuse, and the University of Cambridge (UK). He also directs psychopharmacology services and academic programs for the five facility, 6500 patient California Department of State Hospital System where he has a leadership role in addressing violence and decriminalization of the seriously mentally ill in the five-hospital 6500 patient DSH. Dr. Stahl was formerly Executive Director of Clinical Neurosciences at the Merck Neuroscience Research Center in the UK for several years. Dr. Stahl’s major interests are dedicated to producing and disseminating educational information about diseases and their treatments in psychiatry and neurology.

Dr. Stahl currently serves as editor-in-chief of CNS Spectrums. He is also past associate editor of Acta Psychiatrica Scandinavica, former clinical field editor for the International Journal of Neuropsychopharmacology and is currently on numerous editorial boards of other leading journals including the ACNP’s journal Neuropsychopharmacology. He has conducted numerous research projects during his career awarded by the National Institute of Mental Health (NIMH), by the Department of Veteran Affairs (VA) and by the pharmaceutical industry. Author of over 550 articles and chapters with an H index of 62, and more than 1800 scientific presentations and abstracts, Dr. Stahl is an internationally renowned clinician, researcher, and teacher in psychiatry with subspecialty expertise in psychopharmacology. Dr. Stahl has written 44 books and edited 14 others, including the best-selling and award-winning textbook, Stahl’s Essential Psychopharmacology, now in its fourth edition, and the best-selling and award-winning clinical manual, Essential Psychopharmacology Prescriber’s Guide, now in its sixth edition. Dr. Stahl has also published a novel, Shell Shock, a thriller that recounts the history of PTSD (post-traumatic stress disorder).

Lectures, courses, and preceptorships based upon his textbooks have taken him to dozens of countries on 6 continents to speak to tens of thousands of physicians, mental health professionals and students at all levels. His books have sold over a million copies and his lectures and scientific presentations have been distributed as more than a million CD-ROMs, internet educational programs, videotapes, audiotapes, and programmed home study texts for continuing medical education to hundreds of thousands of professionals in many different languages. His courses and award-winning multimedia teaching materials are used by psychopharmacology teachers and students throughout the world.

Dr. Stahl serves as a fellow of the ACNP (American College of Neuro-psychopharmacology), of the British Association of Psychopharmacology (BAP) and of the CINP, where he was formerly vice president and is a Distinguished Life Fellow of the American Psychiatric Association (APA). He also has served on numerous medical and scientific advisory boards for the pharmaceutical industry, for the biotechnology and medical information industry, and for various nonprofit and public service organizations, including appointment by the State of California and past Chair of the Medi-Cal Oversight Board for Medicines (Drug Utilization Review Board).

He has been awarded the International College of Neuropsychopharmacology (CINP) Lundbeck Foundation Award in Education for his contributions to postgraduate education in psychiatry and neurology. His books have won the British Medical Association’s Book of the Year Award, and recently awarded the 2016 British Medical Association’s First Place Award for his Digital Masterclass in Psychopharmacology accredited by Cambridge University Health Partners and the Department of Psychiatry at the University of Cambridge, UK, where he is a Fellow. Dr. Stahl is also the winner of the A.E. Bennett Award of the Society of Biological Psychiatry, the APA/San Diego Psychiatric Society Education Award, the UCSD department of psychiatry residency teaching award, and has been cited as both one of “America’s Top Psychiatrists” and one of the “Best Doctors in America.” He was honored with the Distinguished Psychiatrist Award of the APA and gave the Distinguished Psychiatrist Lecturer for 2013. Recently, his alma mater Northwestern University honored him by naming their annual award for the best medical student going into psychiatry the Stephen Stahl award. Dr. Stahl was named the 2016 David A Mrazek Memorial Award Winner by the American Psychiatric Association and delivered the Mrazek Lecture at the 2016 annual meeting of the APA. In 2018 he was awarded an Honorary Doctorate of Science by Üsküdar University in Istanbul. In 2018, Dr. Stahl was invited by the Vatican in Rome to cofound a School of Psychopharmacology, Psychopharmacology and Neuroethics at the Vatican’s European University of Rome in Vatican City, to deal with policy issues to lessen the burden of the seriously mentally ill by bringing together leaders in psychiatry under the auspices of Pope Francis, along with world leaders from government and academia.

Curriculum Vitae